CN115315434A - 白细胞介素15融合蛋白和前药及其组合物和方法 - Google Patents

白细胞介素15融合蛋白和前药及其组合物和方法 Download PDF

Info

Publication number
CN115315434A
CN115315434A CN202080095025.8A CN202080095025A CN115315434A CN 115315434 A CN115315434 A CN 115315434A CN 202080095025 A CN202080095025 A CN 202080095025A CN 115315434 A CN115315434 A CN 115315434A
Authority
CN
China
Prior art keywords
fusion protein
cells
cell
receptor
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095025.8A
Other languages
English (en)
Chinese (zh)
Inventor
王阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Targeting Inc
Original Assignee
Immune Targeting Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Targeting Inc filed Critical Immune Targeting Inc
Publication of CN115315434A publication Critical patent/CN115315434A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080095025.8A 2019-12-05 2020-12-04 白细胞介素15融合蛋白和前药及其组合物和方法 Pending CN115315434A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944203P 2019-12-05 2019-12-05
US62/944,203 2019-12-05
PCT/US2020/063214 WO2021113577A1 (en) 2019-12-05 2020-12-04 Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof

Publications (1)

Publication Number Publication Date
CN115315434A true CN115315434A (zh) 2022-11-08

Family

ID=76222692

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095025.8A Pending CN115315434A (zh) 2019-12-05 2020-12-04 白细胞介素15融合蛋白和前药及其组合物和方法

Country Status (5)

Country Link
US (1) US20220402988A1 (https=)
EP (1) EP4069725A4 (https=)
JP (1) JP2023503868A (https=)
CN (1) CN115315434A (https=)
WO (1) WO2021113577A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113255A1 (zh) * 2023-11-28 2025-06-05 北京昌平实验室 抗肿瘤抗体与白介素15前体的双功能复合分子及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021207669A1 (en) 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
JP2023540629A (ja) * 2020-09-16 2023-09-25 ベイジーン リミテッド インターロイキン１５構築物及び使用方法
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
US20230035308A1 (en) * 2021-07-02 2023-02-02 Aetio Biotherapy, Inc. Activatable monomeric cytokine-single chain (sc) fc fusion proteins and uses thereof
CA3238283A1 (en) * 2021-11-15 2023-05-19 Yangxin Fu Fusion protein construct taking interleukin 15 as active ingredient and use thereof
JP2025507733A (ja) * 2022-02-28 2025-03-21 ウーシー バイオロジクス アイルランド リミテッド Ｉｌ－１５変異体を含むヘテロ二量体ポリペプチド錯体とその使用
EP4695281A1 (en) * 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
CN120936384A (zh) * 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120177595A1 (en) * 2010-09-21 2012-07-12 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
WO2019213517A1 (en) * 2018-05-04 2019-11-07 Immune Targeting Inc. Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011450C (en) * 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP2553101A4 (en) * 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
PT3444271T (pt) * 2013-08-08 2022-01-05 Inst Nat Sante Rech Med Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
CA3141626A1 (en) * 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120177595A1 (en) * 2010-09-21 2012-07-12 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
CN105017429A (zh) * 2010-09-21 2015-11-04 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
WO2019213517A1 (en) * 2018-05-04 2019-11-07 Immune Targeting Inc. Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JINGYA GUO 等: "Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity", CELL RESEARCH, vol. 31, no. 11, 10 August 2021 (2021-08-10), pages 1190 - 1198, XP037606825, DOI: 10.1038/s41422-021-00543-4 *
QIYUE HU 等: "Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy", SCIENTIFIC REPORTS, vol. 8, no. 1, 16 May 2018 (2018-05-16), pages 055491167 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113255A1 (zh) * 2023-11-28 2025-06-05 北京昌平实验室 抗肿瘤抗体与白介素15前体的双功能复合分子及其应用

Also Published As

Publication number Publication date
EP4069725A1 (en) 2022-10-12
EP4069725A4 (en) 2024-01-10
WO2021113577A1 (en) 2021-06-10
US20220402988A1 (en) 2022-12-22
JP2023503868A (ja) 2023-02-01

Similar Documents

Publication Publication Date Title
JP7684047B2 (ja) インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法
CN115315434A (zh) 白细胞介素15融合蛋白和前药及其组合物和方法
Fu et al. Engineering cytokines for cancer immunotherapy: a systematic review
ES2704411T3 (es) Proteínas de fusión inmunomoduladoras y procedimientos de fabricación de las mismas
US10822419B2 (en) Masking chimeric antigen receptor T cells for tumor-specific activation
AU2022201762A1 (en) IL-15 variants and uses thereof
CN108250303B (zh) 单域抗体融合蛋白及其应用
TW201827455A (zh) 用於治療癌症之表現膜錨定il-12之t細胞
WO2022015711A1 (en) Fusion proteins of anti-pd-l1 and attenuated interferon, and compositions and therapeutic methods thereof
CN118451096A (zh) 异二聚体fc细胞因子及其用途
US11512141B2 (en) Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment
JP2023512657A (ja) Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
JP2026501506A (ja) Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
US20260070957A1 (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
US20210393753A1 (en) Fgl2 neutraling cell therapy and methods of use thereof
RU2757502C1 (ru) Генетическая кассета, содержащая кодон-оптимизированные нуклеотидные последовательности генов TRAIL, PTEN и IFNβ-1, и фармацевтическая композиция для лечения онкологических заболеваний
HK40050872A (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
HK40050873A (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination